Galecto's Participation in Investor Conferences
Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and severe liver diseases, has announced its exciting lineup for participation in several prominent investor conferences. These events provide an opportunity for the company to showcase its advancements in the medical field and connect with potential investors.
Oppenheimer's 35th Annual Healthcare Life Sciences Conference
One of the notable events is the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Galecto will feature a corporate presentation accompanied by one-on-one meetings, allowing insights into its current projects and future endeavors. This presentation is scheduled for Wednesday, February 12, during the time frame of 8:40 to 9:10 AM in a virtual format. Investors can look forward to a live webcast of this engaging presentation on Galecto's investor relations webpage, offering a comprehensive overview of the company's pipeline and strategic goals.
Live Webcast Details
The live presentation will be accessible via the Upcoming Events section of Galecto's investor relations website, with a recorded version set to be available for 90 days following the event. This ensures that those who couldn't attend the live session still have the chance to learn about Galecto's cutting-edge developments.
Leerink Partners Global Healthcare Conference
Following the Oppenheimer conference, Galecto will also participate in the Leerink Partners Global Healthcare Conference, focused on one-on-one meetings. This event provides a platform for personalized discussions between Galecto’s management team and investors. While the exact schedule for this event isn’t specified, it’s another critical chance for investors to engage directly with the company.
37th Annual ROTH Conference
Additionally, Galecto is slated to present at the 37th Annual ROTH Conference, set to unfold over two days, March 17 and 18. This event will also include a corporate presentation, similar to the Oppenheimer conference, along with one-on-one meetings. It places Galecto’s innovative approach to treating formidable diseases front and center, fostering connections with key stakeholders.
Galecto’s Innovative Pipeline
Galecto is committed to delivering breakthroughs in treating cancer and liver diseases. Notably, its pipeline features several first-in-class small molecule drug candidates targeting critical pathways in cancer and fibrosis. Their leading candidate, GB1211, is an orally active galectin-3 inhibitor aimed at treating liver cirrhosis. This therapy shows significant promise, particularly in combination with checkpoint inhibitors for various oncology applications.
Recent Advancements and Future Directions
The company has also made headlines with the recent acquisition of BRM-1420, a preclinical dual inhibitor that targets ENL-YEATS and FLT3. This candidate holds potential for addressing multiple genetic subsets of acute myeloid leukemia (AML). Such advancements underscore Galecto’s commitment to advancing therapies that can make a substantial difference in patient outcomes.
Staying Informed
In the spirit of transparency and maintaining open communication with its stakeholders, Galecto plans to utilize its website to disclose material non-public information consistently. This is a vital step towards building trust and ensuring that investors remain informed about the company's progress and initiatives.
Contact for More Information
For more inquiries, investors are encouraged to reach out to Sandya von der Weid, who can be contacted via email at svonderweid@lifesciadvisors.com or by phone at +41 78 680 0538. Staying connected with the company through these contacts can provide investors with additional insights into Galecto’s evolving landscape.
Frequently Asked Questions
What is Galecto's focus area?
Galecto is primarily focused on developing novel treatments for cancer and severe liver diseases.
When is the Oppenheimer conference?
The Oppenheimer conference will take place on February 12, featuring a corporate presentation and one-on-one meetings.
Where can I watch the live presentation?
The live presentation can be accessed through the Upcoming Events section of Galecto's investor relations website.
What are Galecto's lead drug candidates?
Galecto's lead drug candidates include GB1211, an orally active galectin-3 inhibitor targeting liver cirrhosis, and BRM-1420 for certain types of AML.
Who can I contact for more information about Galecto?
Investors can contact Sandya von der Weid for more inquiries regarding Galecto's plans and progress.
